| Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model D Yedlapudi, GS Joshi, D Luo, SV Todi, AK Dutta Scientific reports 6 (1), 38510, 2016 | 63 | 2016 |
| Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure–Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl … B Das, S Vedachalam, D Luo, T Antonio, MEA Reith, AK Dutta Journal of medicinal chemistry 58 (23), 9179-9195, 2015 | 43 | 2015 |
| A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn-and MPTP-induced toxicities in vivo B Das, S Rajagopalan, GS Joshi, L Xu, D Luo, JK Andersen, SV Todi, ... Neuropharmacology 123, 88-99, 2017 | 37 | 2017 |
| Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Design, Synthesis, and Evaluation of Analogues with Improved Potency and G-protein … RS Crowley, AP Riley, AF Alder, RJ Anderson III, D Luo, S Kaska, ... ACS chemical neuroscience 11 (12), 1781-1790, 2020 | 28 | 2020 |
| Novel multifunctional dopamine D2/D3 receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties D Luo, H Sharma, D Yedlapudi, T Antonio, MEA Reith, AK Dutta Bioorganic & medicinal chemistry 24 (21), 5088-5102, 2016 | 28 | 2016 |
| Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson’s disease with … D Yedlapudi, L Xu, D Luo, GB Marsh, SV Todi, AK Dutta Scientific Reports 9 (1), 19648, 2019 | 19 | 2019 |
| The Salvinorin analogue, Ethoxymethyl ether Salvinorin B, promotes Remyelination in preclinical models of multiple sclerosis KF Paton, K Robichon, N Templeton, L Denny, A Al Abadey, D Luo, ... Frontiers in neurology 12, 782190, 2021 | 16 | 2021 |
| Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent SL Hedrick, D Luo, S Kaska, KK Niloy, K Jackson, R Sarma, J Horn, ... Journal of Biomedical Science 28, 1-18, 2021 | 16 | 2021 |
| Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats. SN Khatri, S Sadek, PT Kendrick Jr, EO Bondy, M Hong, S Pauss, D Luo, ... Experimental and clinical psychopharmacology 32 (2), 150, 2024 | 15 | 2024 |
| Discovery of a potent highly biased MOR partial agonist among diastereomeric C9-hydroxyalkyl-5-phenylmorphans JA Lutz, A Sulima, ES Gutman, EW Bow, D Luo, S Kaska, TE Prisinzano, ... Molecules 28 (12), 4795, 2023 | 11 | 2023 |
| The multifunctional dopamine D2/D3 receptor agonists also possess inhibitory activity against the full-length tau441 protein aggregation I Ziu, I Rettig, D Luo, A Dutta, TM McCormick, C Wu, S Martic Bioorganic & medicinal chemistry 28 (18), 115667, 2020 | 10 | 2020 |
| Dopamine agonists in treatment of Parkinson's disease: an overview D Luo, M Reith, AK Dutta Diagnosis and Management in Parkinson's Disease, 445-460, 2020 | 10 | 2020 |
| A journey through diastereomeric space: the design, synthesis, in vitro and in vivo pharmacological activity, and molecular modeling of novel potent diastereomeric MOR agonists … DR Chambers, A Sulima, D Luo, TE Prisinzano, A Goldberg, B Xie, L Shi, ... Molecules 27 (19), 6455, 2022 | 9 | 2022 |
| Sex differences in kappa opioid receptor agonist mediated attenuation of chemotherapy-induced neuropathic pain in mice KF Paton, D Luo, AC La Flamme, TE Prisinzano, BM Kivell Frontiers in Pharmacology 13, 813562, 2022 | 9 | 2022 |
| Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development IM Henderson, F Zeng, NH Bhuiyan, D Luo, M Martinez, J Smoake, F Bi, ... Biochemical pharmacology 195, 114868, 2022 | 4 | 2022 |
| D-685 Reverses Motor Deficits and Reduces Accumulation of Human α-Synuclein Protein in Two Different Parkinson’s Disease Animal Models AK Dutta, C Armstrong, D Luo, B Das, B Spencer, RA Rissman ACS Chemical Neuroscience 14 (5), 885-896, 2023 | 3 | 2023 |
| A MOR Antagonist with High Potency and Antagonist Efficacy among Diastereomeric C9-Alkyl-Substituted N-Phenethyl-5-(3-hydroxy)phenylmorphans DR Chambers, A Sulima, D Luo, TE Prisinzano, AE Jacobson, KC Rice Molecules 28 (14), 5411, 2023 | 2 | 2023 |
| Discovery of Potent Kappa Opioid Receptor Agonists Derived from Akuammicine MR Hennessy, SM Creed, AM Gutridge, LE Rusali, D Luo, B Sepehri, ... Journal of Medicinal Chemistry 67 (23), 20842-20857, 2024 | 1 | 2024 |
| Searching for Synthetic Opioid Rescue Agents: Identification of a Potent Opioid Agonist with Reduced Respiratory Depression LY Vu, D Luo, K Johnson, ED Denehy, JC Songrady, J Martin, R Trivedi, ... Journal of Medicinal Chemistry 67 (11), 9173-9193, 2024 | 1 | 2024 |
| Potent MOR Agonists from 2′-Hydroxy-5, 9-dimethyl-N-phenethyl Substituted-6, 7-benzomorphans and from C8-Hydroxy, Methylene and Methyl Derivatives of N-Phenethylnormetazocine M Das, GW Ward, A Sulima, D Luo, TE Prisinzano, GH Imler, AT Kerr, ... Molecules 28 (23), 7709, 2023 | 1 | 2023 |
